Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Immunovant Inc., 3 years.
Immunovant Inc.
Director
Arbutus Biopharma Corporation
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Arbutus Biopharma Corporation May 22, 202495.0%
-
Arbutus Biopharma Corporation May 24, 202395.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | Roivant Sciences Ltd. | Shares withheld for tax | −40,310 | $35.39 | $1,426,571 |
| Apr 7, 2026 | Immunovant Inc. | Grant or award | +174,189 | — | — |
| Mar 31, 2026 | Roivant Sciences Ltd. | Shares withheld for tax | −160,035 | $27.70 | $4,432,970 |
| Feb 23, 2026 | Roivant Sciences Ltd. | Option exercise | +587,390 | $3.85 | $2,261,452 |
| Feb 23, 2026 | Roivant Sciences Ltd. | Open-market sale | −587,390 | $27.51 | $16,159,099 |
| Feb 20, 2026 | Roivant Sciences Ltd. | Option exercise | +1,012,610 | $3.85 | $3,898,549 |
| Feb 20, 2026 | Roivant Sciences Ltd. | Open-market sale | −1,012,610 | $27.15 | $27,492,362 |
| Feb 19, 2026 | Roivant Sciences Ltd. | Option exercise | +1,400,000 | $3.85 | $5,390,000 |
| Feb 19, 2026 | Roivant Sciences Ltd. | Open-market sale | −1,400,000 | $27.42 | $38,388,000 |
| Dec 24, 2025 | Roivant Sciences Ltd. | Other | −64,891 | $22.47 | $1,458,101 |
| Dec 24, 2025 | Roivant Sciences Ltd. | Gift | −110,489 | — | — |
| Dec 23, 2025 | Roivant Sciences Ltd. | Grant or award | +175,380 | $22.45 | $3,937,281 |
| Jul 30, 2025 | Roivant Sciences Ltd. | Grant or award | +1,836,547 | — | — |
| Jul 30, 2025 | Roivant Sciences Ltd. | Grant or award | +11,900,000 | — | — |
| Apr 1, 2025 | Immunovant Inc. | Grant or award | +199,365 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.